Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2098 PWToday Stories


17 Mar 17

Cancer charity Myeloma UK, has launched MUK eleven, a first of its kind immunotherapy trial which aims to modulate the immune system to target myeloma. The Phase 1b trial will study oncolytic virus, Reolysin® (pelareorep), in combination with immunomodulatory drugs (IMiDs) as a rescue treatment in relapsing myeloma patients.


Reolysin has been shown to be effective in killing a range of cancer cells including myeloma cells. In addition, researchers at the University of Leeds have undertaken studies which suggest an increase in immune activation when Reolysin is combined with IMiDs in myeloma cells.


In MUK eleven, this novel oncolytic treatment will be combined with Imnovid® (pomalidomide) or Revlimid® (lenalidomide) in patients whose myeloma is progressing whilst on these IMiD treatments. The dose escalation trial will look at the safety and tolerability of these combinations, and will investigate whether the addition of Reolysin extends disease control in this patient group.


MUK eleven Chief Investigator Gordon Cook said, “This trial, the first of its kind, is a novel way of activating a patient’s own immune system to target their myeloma (immunotherapy) using a natural virus and lenalidomide or pomalidomide, which could offer a new treatment strategy in myeloma.”


The trial will aim to recruit 44 patients across up to six Myeloma UK Clinical Trial Network centres in the UK. MUK eleven is part of the Myeloma UK Clinical Trial Network, a portfolio of early stage trials co-ordinated by the Clinical Trials Research Unit at the University of Leeds, which aims to test and speed up access to promising new treatments for patients.


Myeloma UK Director of Research Dr Simon Ridley said, “We focus on strategic, collaborative and innovative approaches to delivering trials and treatments to patients. Our Clinical Trial Network is focused on ensuring that patients now and in the future are getting access to the exciting new treatment combinations we are seeing coming down the line, and so we are pleased to launch this novel trial which focuses on a pivotal area of myeloma research.”


Oncolytics Biotech Inc. (Reolysin) and Celgene UK & Ireland (Imnovid and Revlimid) will provide their respective treatments for the MUK eleven trial.


“This is an important collaboration for Oncolytics as we work to pair Reolysin with innovative immuno-modulatory agents,” said Dr Matt Coffey, President and CEO of Oncolytics. “We are eager to see if new combinations can exhibit the same risk-benefit profile observed in other studies.” 


Dr Adrian Kilcoyne, Celgene UK and Ireland Medical Director adds, “Celgene is delighted to be involved in this research with the Institute of Cancer Research, the University of Leeds, Myelo

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.